Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OTC labeling studies "procedural, methodological flaws" cited in NDMA letter to OMB.

This article was originally published in The Tan Sheet

Executive Summary

FDA OTC LABELING STUDIES "PROCEDURAL, METHODOLOGICAL FLAWS" CITED BY NDMA in a June 13 letter to the Office of Management & Budget. The Nonprescription Drug Manufacturers Association asks OMB to withhold approval of FDA's proposed consumer label comprehension studies and to deny the agency's request that the office apply an expedited, or "emergency," review procedure to the research project. FDA's planned labeling studies, involving over 2,000 subjects, are intended to evaluate the format changes proposed by the agency in February and gather information about consumer preferences for label design variations ("The Tan Sheet" May 26, p. 4).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel